Modality
Degrader
MOA
RAS(ON)i
Target
GPRC5D
Pathway
Notch
RCC
Development Pipeline
Preclinical
~Aug 2021
→ ~Nov 2022
Phase 1
Feb 2023
→ Mar 2028
Phase 1Current
NCT04734561
2,621 pts·RCC
2023-02→2028-03·Terminated
2,621 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-192.0y awayInterim· RCC
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Termina…
Catalysts
Interim
2028-03-19 · 2.0y away
RCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04734561 | Phase 1 | RCC | Terminated | 2621 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D |